Arcturus Therapeutics In... (ARCT)
NASDAQ: ARCT
· Real-Time Price · USD
20.31
-0.14 (-0.68%)
At close: Sep 25, 2025, 3:59 PM
20.30
-0.05%
After-hours: Sep 25, 2025, 05:21 PM EDT
-0.68% (1D)
| Bid | 20.1 |
| Market Cap | 551.51M |
| Revenue (ttm) | 117.5M |
| Net Income (ttm) | -60.16M |
| EPS (ttm) | -2.22 |
| PE Ratio (ttm) | -9.15 |
| Forward PE | -8.34 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 20.95 |
| Volume | 407,641 |
| Avg. Volume (20D) | 693,445.2 |
| Open | 19.74 |
| Previous Close | 20.45 |
| Day's Range | 19.56 - 20.50 |
| 52-Week Range | 8.04 - 25.88 |
| Beta | 2.39 |
| Ex-Dividend Date | n/a |
About ARCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsArcturus Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+29.01%
Arcturus Therapeutics Holdings shares are trading ...
Unlock content with
Pro Subscription
1 month ago
+30.73%
Arcturus Therapeutics Holdings shares are trading higher after the company reported better-than-expected Q2 financial results. Citigroup maintained a Buy rating on the stock and raised its price target from $47 to $49
2 months ago · https://thefly.com
Citi adds 'upside 90-day catalyst watch' on Arcturus Therapeutics08 Jul 09 Jul
